Company intelligence / Profile preview

ReSync Bio

United States

Ownership: Private
Development stage: Other

Overview

ReSync Bio developed and commercialized a data automation platform for preclinical drug discovery, supporting faster coordination, permissioning, and integration across R&D, labs, and CROs. The platform accelerated efficiency for therapeutic development by streamlining experimental and computational workflows. Following acquisition by Benchling, the ReSync platform is being sunsetted and will transition to Benchling’s infrastructure

Industry: Drug Discovery Services

Partnerships

NVIDIA BioNeMo (AI drug discovery industry partnership)Rowan (commercial partner)

Beyond the preview

Go deeper on ReSync Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReSync Bio.

Explore the full profile